Jump to content

Draft:Deep Breathe

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Citation bot (talk | contribs) at 16:27, 26 December 2023 (Add: pmc, authors 1-1. Removed parameters. Some additions/deletions were parameter name changes. | Use this bot. Report bugs. | #UCB_CommandLine). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Deep Breathe is a Canadian medical technology company headquartered in London, Ontario that utilizes artificial intelligence software in conjunction with medical ultrasound.[1]

Founding

In May 2020, Robert Arntfield, a researcher, doctor, and the Medical Director of the Critical Care Trauma Centre at London Health Sciences Centre, began work with a team at Lawson Health Research Institute to investigate how artificial intelligence systems can be used to diagnose COVID-19 through patterns in lung scans.[2] During the project, a study involved the real-time validation of a lung ultrasound learning model in intensive care units, demonstrating high accuracy in identifying B-line patterns in critically ill patients. This system also demonstrated high accuracy and surpassed physicians in detecting COVID-19 in lung ultrasounds.[3] This system became the first product for his medical technology company, Deep Breathe, which he founded in 2021.[1]

Product

The company provides artificial intelligence software to automate the interpretation of medical images. Algorithms are used to analyze and interpret ultrasound images to make diagnoses by healthcare providers.[1] The intended use is in conjunction with handheld, point-of-care lung ultrasound technology which the company purports can enable healthcare providers to diagnose various lung conditions with speed, accuracy, and objectivity.[4] Currently, the software utilizes Deep Breathe’s archive of lung ultrasound images, which is the largest in the world and spans over a decade of clinical research.[1]  

The product can aid in diagnosing COVID-19, congestive heart failure, pneumonia, pleural effusion, and pneumothorax, among other conditions.[5]

Operations

In February 2023, Deep Breathe received an external investment from MAP Equity Investco, an investment firm based in London, Ontario. This investment accelerated regulatory approval efforts with Health Canada and the United States Food and Drug Administration.[5] Following regulatory approval, the company will seek out partnerships with manufacturers to add Deep Breathe technology into ultrasound hardware.[1]

References

  1. ^ a b c d e De Bono, Norman (2023-03-09). "London doctor aims to bring AI technology to diagnosing lung woes". The London Free Press. Retrieved 2023-12-08.
  2. ^ "London, Ont. researchers examining use of A.I. to diagnose COVID-19 through lung ultrasounds | Globalnews.ca". 980 CFPL. Retrieved 2023-12-08.
  3. ^ Arntfield, Robert; VanBerlo, Blake; Alaifan, Thamer; Phelps, Nathan; White, Matthew; Chaudhary, Rushil; Ho, Jordan; Wu, Derek (2021-03-01). "Development of a convolutional neural network to differentiate among the etiology of similar appearing pathological B lines on lung ultrasound: a deep learning study". BMJ Open. 11 (3): e045120. doi:10.1136/bmjopen-2020-045120. ISSN 2044-6055. PMC 7939003. PMID 33674378.
  4. ^ Bieman, Jennifer (2021-03-22). "London-schooled AI is flawless at detecting COVID in lung ultrasounds". The London Free Press. Retrieved 2023-12-08.
  5. ^ a b "Western prof develops AI-powered bedside lung ultrasound". Western News. 2023-03-27. Retrieved 2023-12-08.


Category:Service companies of the United States